ReviewJournal of the National Cancer Institute. Monographs2020
Updated Overview of the SEER-Medicare Data: Enhanced Content and Applications.
Review in Journal of the National Cancer Institute. Monographs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 171 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
171 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune-related conditions and cancer-specific mortality among older adults with cancer in the United States.International journal of cancer · 2022Pooled it
- Changes in opioid prescribing and high-risk co-prescribing after implementation of the 2016 CDC opioid guideline among older adults with and without cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer?Annals of surgical oncology · 2026Article
- Uncovering hypothesis-generating associations between prescription drugs and digestive cancer risk: a case-control drug-wide association study (DWAS).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Increased Heart Failure Risk with Gastric Cancer Progression: A Nationwide Population-Based Cohort Study.Gut and liver · 2026Article
- Measurement of Treatment Adequacy Influences Racial Disparities Estimates in Endometrial Cancer Care.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Type 2 Diabetes Risk Among Older Asian, Native Hawaiian and Pacific Islander Patients With Head and Neck Cancer in the United States.Cancer medicine · 2026Article
- Palliative Care for Advanced Cancer in Medicare Advantage and Physician Networks.JAMA network open · 2026Article
- Patterns of Multimorbidity among Older Adults with Colorectal Cancer Living in Puerto Rico.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Article
- Rationale and Methods of a Surveillance System for Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies: A Qualitative Participatory Action Research Approach in Middle-Income Countries-The Experience in Iran.Health science reports · 2026Article
- Mortality after emergency presentation: evidence from a cohort of 929 378 Medicare beneficiaries with common cancers diagnosed 2008-2017.Journal of the National Cancer Institute · 2026Article
- Risk of fracture following androgen receptor pathway inhibitors in men with advanced prostate cancer.Journal of the National Cancer Institute · 2026Article
- Oncology Organization and Oncologist Networks Under Medicare Advantage Plans.JAMA network open · 2026Article
- Longitudinal dynamics of post-diagnosis frailty among older women with ovarian cancer.Gynecologic oncology · 2026Article
- Access to Specialty Cancer Care and Plan Disenrollment Among Medicare Beneficiaries.JAMA network open · 2026Article
- Risk of late recurrence of colorectal and breast cancer among older long-term cancer survivors.JNCI cancer spectrum · 2026Article
- Agreement between Surveillance, Epidemiology, and End Results- and Medicare Claims-Derived Uterine Cancer Treatment Data.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Article
- Short-and Long-term Patient Outcomes in Hospitals Primarily Serving Patients with Colorectal Cancer from High-Poverty Areas-An Observational Cohort Study.Annals of surgical oncology · 2026Observational
111 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database was first created almost 30 years ago. Over time, additional data have been added to the SEER-Medicare database, allowing for expanded insights into the delivery of health care across the cancer continuum from screening to end of life.
methodsThis article includes an overview of the current SEER-Medicare database, presenting potential users with an introduction to how the data can facilitate innovative epidemiologic and health services research studies. With a focus on the population 65 years and older, this article presents descriptive data on beneficiary demographics, cancer characteristics, service settings, Medicare coverage (eg, Parts A, B, C, and D), and use (number of services or bills) from 2011 to 2015.
resultsFrom 2011 to 2015, 857 056 cancer patients and 601 470 population-based noncancer controls were added to the database. The database includes detailed tumor characteristics and clinical assessments for cancer cases, and demographics and health-care use (eg, hospitals, outpatient facilities, individual providers, hospice, home health-care providers, and pharmacies) for both cases and controls. Although characteristics varied overall between cases and controls, sufficient cancer-specific matched controls are available. Roughly 60% of cases were enrolled in fee for service at cancer diagnosis. The annual average number of claims per case was 60.7 and 92.3 during the year before and after cancer diagnosis, respectively, and 127.5 during the year before death.
conclusionsThe large sample size and diverse array of data on cancer patients and noncancer controls in the SEER-Medicare database make it a unique resource for conducting cancer health services research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.